Clinical trials: Botox
Glabellar Frown Lines
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase Ⅲ clinical trials. In Phase Ⅲ, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a…
- Trial name
- NCT05364580
- Testing
- PROTOXIN, Botox®
- Where
- 5 sites in South Korea
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Spasticity
Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type A
The aim of the study is to describe the long term use of Botulinum Neurotoxin Type A (BoNT-A) in adult subjects affected with upper and/or lower limb spasticity who received treatment with BoNT-A for a minimum of three injections…
- Trial name
- RESULT (NCT04340336)
- Where
- 3 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Ipsen
Chronic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine.
- Trial name
- C-BEOND (NCT06047444)
- Testing
- Botulinum toxin type A
- Where
- 120 sites in United States, Canada and 7 more
- Volunteers
- 759 people
- Sponsor
- Ipsen
Benign Prostatic Hyperplasia
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study will evaluate the safety and efficacy of intraprostatic administration of botulinum toxin Type A (BOTOX®) compared with placebo to treat urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT01107392
- Testing
- botulinum toxin Type A, Normal saline
- Where
- 8 sites in United States, Canada and 6 more
- Volunteers
- 315 people
- Sponsor
- Allergan
Glabellar Frown Lines
Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
This was a pilot study to observe patient satisfaction with BOTOX® Cosmetic treatment in glabellar rhytides (frown lines) using a new treatment satisfaction measure.
- Trial name
- NCT01391312
- Testing
- botulinum toxin Type A
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Allergan
Moderate to Severe Glabellar Lines
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
The purpose of this study was to demonstrate the safety and the efficacy of a single treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC; hereafter referred to as…
- Trial name
- BTX-A-HAC NG (NCT02353871)
- Testing
- Botulinum toxin type A
- Where
- 9 sites in France, Germany
- Volunteers
- 185 people
- Sponsor
- Ipsen
Cervical Dystonia Adults ,, Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
ASIS for Botox in Cervical Dystonia
Botox acts on nerve endings, yet there are no nerve endings inside the muscle, where they are typically injected. All nerves terminate on the fascia, where ASIS device can precisely deliver Botox by creating that subdermal…
- Trial name
- ASISinCD (NCT02074293)
- Testing
- Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- li nguyen
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Chronic Migraine
Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA (BOTOX®) in adults with chronic migraine.
- Trial name
- NCT01833130
- Testing
- OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Allergan
Stroke, Upper Limb Spasticity
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
The purpose of this study is to investigate if early administration (i.e. within 12 weeks after stroke) of Dysport® 500 U injections may delay the appearance or the progression of upper limb symptomatic spasticity.
- Trial name
- ONTIME Pilot (NCT02321436)
- Testing
- Botulinum toxin type A
- Where
- 4 sites in Malaysia, Philippines and 2 more
- Volunteers
- 42 people
- Sponsor
- Ipsen
Upper Facial Lines, Glabellar Lines
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combination in adult participants with moderate to severe upper facial lines.
- Trial name
- NCT07871513
- Testing
- TrenibotulinumtoxinE and OnabotulinumtoxinA, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- AbbVie
Facial Rhytides, Crow's Feet Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines
- Trial name
- NCT01189760
- Testing
- onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 917 people
- Sponsor
- Allergan
Trigeminal Neuralgia
Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia
To evaluate the efficacy of different dosing regimens of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of trigeminal neuralgia (TN), so as to determine the optimal dosing regimen of the best administration…
- Trial name
- NCT06410859
- Testing
- Botulinum Toxin Type A for Injection,also known as "HengLi®"
- Where
- China
- Volunteers
- 240 people
- Sponsor
- LKGS_277
Upper Limb Spasticity Post-Stroke
Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke
This study aims to estimate the costs of botulinum toxin A utilization in standard practice for the treatment of upper limb spasticity post-stroke in Portugal.
- Trial name
- P_Dysport_CS (NCT02384330)
- Where
- 3 sites in Portugal
- Volunteers
- 57 people
- Sponsor
- Ipsen
Spasmodic Torticollis
PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia
The safety and efficacy of Mentor Purified Toxin, Botulinum Toxin Type A, Purified Neurotoxin, injected intramuscularly into the neck, is being evaluated as a treatment for painful and non-painful spasmodic torticollis/cervical…
- Trial name
- NCT00549341
- Testing
- Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin, Physiologic saline
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Mentor Worldwide, LLC
Moderate to Severe Glabellar Line
Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line
The purpose of this study was to observe Efficacy and safety of DWP450 compared with Botox in moderate to severe glabellar line patients.
- Trial name
- NCT01629875
- Testing
- Generic equivalent of Clostridium Botulinum A Toxin, Botox (Clostridium Botulinum A Toxin)
- Where
- South Korea
- Volunteers
- 268 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Urinary Bladder, Overactive, Urinary Bladder, Neurogenic
Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder
This study will describe the prescription conditions of botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) or idiopathic overactive bladder (IOAB) as…
- Trial name
- BOREAL (NCT02673047)
- Testing
- botulinum toxin Type A
- Where
- 50 sites in France
- Volunteers
- 474 people
- Sponsor
- Allergan
Glabellar Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
- Trial name
- NCT03014635
- Testing
- Botulinum Toxins, Type A
- Where
- 14 sites in United States, Canada
- Volunteers
- 306 people
- Sponsor
- Revance Therapeutics, Inc.
Crow's Feet Lines
A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines
A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines
- Trial name
- NCT04081402
- Testing
- HU-014, Botox Inj
- Where
- South Korea
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Stroke, Spasticity
Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity
The purpose of this study is to evaluate the safety and efficacy of Botulax® compared to Botox® reducing upper limb muscle tone in post stroke patients.
- Trial name
- NCT01915459
- Testing
- Botulinum toxin type A(Botulax®), Botulinum toxin type A(Botox®)
- Where
- 6 sites in South Korea
- Volunteers
- 186 people
- Sponsor
- Hugel